Breast Cancer Prevention and Control Policy

Objectives

The policy establishes a national breast cancer control framework for South Africa, implemented across the public health system to reduce incidence and mortality, improve quality of life, and ensure equitable access to affordable, quality services irrespective of socioeconomic status.[1][2]It aligns with Sustainable Development Goal 3, the National Development Plan 2030 and the planned National Health Insurance system.[3][2]

• Strengthen prevention, breast-health awareness, early detection and risk-stratified screening, particularly through community education, clinical breast examination and prompt assessment of breast changes.[4][5][6]
• Improve timely access to diagnosis through clear referral pathways, specialist breast units, triple assessment, staging and patient navigation.[7][5][8]
• Provide evidence-based treatment spanning surgery, reconstruction, systemic therapy, radiotherapy, palliative care, survivorship support and lymphoedema management.[7][9][10][11][12][13]
• Address higher-risk populations, including women living with HIV, sex workers, adolescents and migrants, while providing genetic assessment, counselling and surveillance for women with inherited susceptibility.[2][14][15]
• Reduce delays, stage at presentation and disease-related morbidity while improving survival, quality of life during survivorship and palliation, and the consistency of care between geographical areas and social groups.[4][16]
• Strengthen data, research, monitoring, follow-up and community engagement as core policy areas.[5][13][17]

The framework is organised around eight key areas and 22 objectives, covering prevention and early detection, timely access, assessment and staging, treatment, palliative care, follow-up and surveillance, data and research, and community engagement.[5]Its clinical rationale is to detect breast cancer at an earlier stage, when smaller cancers generally have better survival prospects and can be treated more effectively and simply.[5]

Implementation

The delivery model centres on designated Specialist Breast Units, linked to primary healthcare, district hospitals, Provincial Oncology Units and, where necessary, services in neighbouring provinces.[18][8]These units should provide coordinated multidisciplinary diagnosis and management, rapid referral, training, audit, survivorship support and palliative-care co-ordination.[8]

• Deliver opportunistic breast education and provider-initiated clinical breast examination in primary care, including biennial examination for women over 40 attending primary health clinics and risk assessment with appropriate triage.[5][6]
• Limit mammography in the public system to symptomatic women and identifiable high-risk patients attending specialist units, because population screening is not considered feasible with current resource and infrastructure constraints.[6]
• Refer symptomatic patients promptly through standardised pathways, allowing immediate transfer from primary care, district or non-specialist regional facilities to a designated specialist unit where required.[19]
• Provide Specialist Breast Assessment within 21 to 45 days according to referral triage, with high- or medium-suspicion cases assessed within 21 days and low-suspicion cases within 60 days.[18][19]
• Undertake triple assessment through clinical examination, imaging and histological confirmation, and complete multidisciplinary review and management planning before referral for specialised oncology services where possible.[20][21]
• Meet treatment timeliness standards by beginning treatment within 60 days of first presentation for 90 per cent of patients, commencing definitive treatment within 31 days of the treatment decision, and starting adjuvant therapy within 60 days of surgery, or no later than 90 days.[22]
• Provide risk-based genetic services, including counselling, testing and management options such as intensified screening, chemoprevention and prophylactic surgery for individuals and families at risk of inherited breast cancer.[14][15]
• Integrate palliative care early for eligible patients with stage 4 disease, supported by nursing staff, specialist services, affordable opioids, trained personnel and home-care programmes where feasible.[23][24]

Multidisciplinary teams should involve breast and reconstructive surgeons, oncologists, radiologists, nuclear physicians, pathologists, geneticists, breast care nurses, psychosocial and rehabilitation staff, palliative-care workers and data personnel.[1][16][25]Each breast unit should be clinically led by a medical Clinical Director of Breast Services, use written protocols agreed and reviewed by its core team, and maintain a minimum annual caseload of 150 newly diagnosed primary breast cancer cases to support expertise and cost-effective functioning.[26]

Community and civil society participation is integral to implementation. Healthcare workers, community healthcare workers, support groups, non-profit organisations, peer educators, traditional leaders, religious leaders and other community decision-makers should help deliver culturally appropriate awareness, counselling, peer support and linkage to screening and care.[17][27][28]Patient navigators, supported through non-governmental organisations and government budget holders, should assist access, information transfer and treatment completion.[8]

Implementation should be supported by continuous audit and electronic data systems. Facilities should collect information from diagnosis throughout the disease course, with a data manager responsible for quality assurance, ethical use and audit requests.[17]Breast-unit registries should record referral source, diagnosis, pathology, treatment intervals, primary treatment and outcomes, while the interval from presentation to definitive diagnosis and first multidisciplinary-team visit should not exceed four weeks.[25]National population-based cancer and mortality registries should provide incidence and mortality data, supported by clinician and pathologist compliance.[13][17]

Key operational measures include annual genetic counselling and genetic-testing coverage, screening uptake, referral and treatment intervals, completion of triple assessment, treatment timing, radiotherapy timeliness, follow-up, and facility-level monthly and annual service figures.[18][22][29][12][13][17]The policy identifies resource needs including trained staff, diagnostic and surgical infrastructure, transport, computerised breast software, patient navigators and specialist capacity, but does not specify a comprehensive budget, financing allocations or funding gaps.[8][19]

Monitoring & Evaluation

The policy establishes a multi-level monitoring, evaluation and accountability approach linking standards of care, service timeliness, clinical quality, patient outcomes, facility reporting and population surveillance. Monitoring and evaluation points are intended to function as key performance indicators derived from the standards of care, while continuous audit is expected in facilities providing breast cancer care.[16][5]

• Monitor programme implementation and the impact of breast cancer interventions, and use an audit framework to assess standards of care and outcomes.[4]
• Collect biannual clinic figures on uptake among eligible women, use audit and comment forms to identify patient-level and facility-level barriers, and assess whether eligible women receive risk determination and management under local protocols.[6]
• Record referrals for genetic assessment, annual genetic counselling figures, and the proportion of patients offered counselling or genetic testing.[14][30]
• Monitor annual screening figures for eligible mutation carriers through monitoring and evaluation point ME7.[18]
• Audit SBU compliance with minimum staffing and functional requirements, individual patient care pathways, and cases through a coordinated national computerised network.[8][19]
• Track referral and treatment timeliness, including specialist assessment within 21 days for high- or medium-suspicion cases and within 60 days for low-suspicion cases.[19]
• Track the target for 90% of patients to begin treatment within 60 days of first presentation, for first definitive treatment within 31 days of a treatment decision, and for adjuvant therapy within 60 days of surgery, with an absolute maximum of 90 days.[22]
• Audit completion of triple assessment, with a target of more than 80% of patients completing it within 21 days, and maintain laboratory internal and external quality-control, assessment and assurance systems.[29][31]
• Monitor treatment-specific measures, including patients discussed by multidisciplinary teams, initiation of neoadjuvant therapy within 30 days of diagnosis, initiation of adjuvant therapy within 90 days of surgery, radiotherapy within 90 days after breast-conserving surgery, and indicated post-mastectomy radiotherapy within 60 days.[32][12]
• Monitor the proportion of eligible patients receiving breast-conserving surgery, node-negative patients receiving axillary lymph node dissection, reconstruction activity and documentation of reconstruction discussions.[33][11]
• Monitor palliative radiotherapy timeliness, including simulation within 60 days and treatment completion within 120 days, and establish each patient's follow-up schedule at treatment completion.[23]

Follow-up standards require clinical review every three months for the first two years, every six months for the following two years and annually thereafter, with annual mammography for patients treated for early or locally advanced cancer and no routine investigations for asymptomatic patients.[24]

Facility-level surveillance should produce reliable monthly and annual figures from primary healthcare facilities, breast units and points of entry. Health facilities should collect electronic data from diagnosis throughout the disease course, while breast units should maintain patient databases for clinical management, surveillance and research.[13][17]A data manager should support data quality assurance, ethical data use and audit responses.[17]

A national population-based cancer registry and mortality registers are intended to provide incidence and mortality data, supported by compliance from diagnosing clinicians and pathologists. Priority data include stage and tumour size at diagnosis and stage-specific survival, enabling assessment of treatment quality, public health burden and targeted policy action.[13][17]The National Cancer Registry currently collates cancer morbidity but is described as pathology-based, incomplete in coverage and not up to date.[4][34]

Specialist Breast Units and Principal Oncology Units should maintain registries and audit databases recording referral source, diagnosis, pathology, diagnostic and multidisciplinary-team intervals, treatment and outcomes. The interval from presentation to definitive diagnosis and first multidisciplinary-team visit should not exceed four weeks, and units should be independently audited against service obligations and national guidelines.[25]

The available material does not specify a unified national reporting template, a comprehensive national indicator dictionary, a fixed evaluation timetable, or named accountability bodies beyond facility requirements, data managers, independent unit audit and provincial coordination.[16][13][25]

Costing & Financing

Breast cancer control is recognised as requiring time and expenditure in a resource-constrained health system facing competing priorities, while the planned National Health Insurance system is identified as a platform for equitable access to affordable, quality services.[4][2]The supplied material does not provide a comprehensive costed implementation plan, overall budget, financing allocation, funding-gap estimate, resource-mobilisation target or formal economic model.[2][17]

• Provide a specialised budget for chemotherapy and biological therapies, although no monetary allocation is specified.[22]
• Negotiate trastuzumab prices with pharmaceutical providers so that treatment does not compromise care in other health sectors; the guidance explicitly excludes trastuzumab treatment costs from its scope.[32]
• Consider availability and affordability when selecting hormonal therapy and HER2-targeted treatment, as the cost of HER2-targeted therapies limits access in South Africa and globally.[35]
• Resource designated Specialist Breast Units with staffing, equipment, multidisciplinary capability, patient navigators and computerised breast software, with government budget holders and non-governmental organisations identified as potential supporters of navigation.[18][8]
• Maintain a minimum annual caseload of 150 newly diagnosed primary breast cancer cases per breast unit to support clinical expertise and cost-effective functioning.[26]
• Prioritise simple, affordable and sustainable screening, particularly where mammography is unavailable or expensive.[36]

Economic modelling cited in the policy suggests that annual clinical breast examination by ancillary health workers between ages 40 and 60 may be nearly as effective as biennial mammography in reducing mortality in developing countries, at substantially lower cost.[36]Mammography is described as expensive and resource-intensive, and its introduction is not advised unless reliable screening can reach at least 70% of women aged 50 years and over.[6]

The policy also frames coordinated surveillance and follow-up as a means to avoid duplicate visits and reduce expenditure associated with oversubscribed central services.[20]Home palliative care is described as feasible and cost-effective in low-resource settings, and access to affordable opioids, trained staff and home-care programmes is identified as necessary.[24]

Educational campaigns may be implemented at low or minimal cost, while structured counselling at primary-care level is intended to be free of charge to users.[27][17]The source does not specify the funding source or provider cost for counselling, nor monetary valuations for follow-up, physiotherapy, data systems, registries, transport, community engagement or palliative care.[13][17]